Novan, Inc. (NOVN): Price and Financial Metrics


Novan, Inc. (NOVN)

Today's Latest Price: $0.51 USD

0.02 (3.06%)

Updated Jul 10 6:55pm

Add NOVN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 213 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

NOVN Stock Summary

  • Novan Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 6.77% of US listed stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -1.78 for Novan Inc; that's greater than it is for merely 5.04% of US stocks.
  • In terms of volatility of its share price, NOVN is more volatile than 98.7% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Novan Inc are ETTX, MVIS, CLDX, CRIS, and LQDA.
  • NOVN's SEC filings can be seen here. And to visit Novan Inc's official web site, go to www.novan.com.
NOVN Daily Price Range
NOVN 52-Week Price Range

NOVN Stock Price Chart Technical Analysis Charts


NOVN Price/Volume Stats

Current price $0.51 52-week high $3.72
Prev. close $0.50 52-week low $0.22
Day low $0.50 Volume 12,055,300
Day high $0.54 Avg. volume 11,476,359
50-day MA $0.45 Dividend yield N/A
200-day MA $1.13 Market Cap 40.57M

Novan, Inc. (NOVN) Company Bio


Novan, Inc. focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris. The company was founded in 2006 and is based in Durham, North Carolina.


NOVN Latest News Stream


Event/TimeNews Detail
Loading, please wait...

NOVN Latest Social Stream


Loading social stream, please wait...

View Full NOVN Social Stream

Latest NOVN News From Around the Web

Below are the latest news stories about Novan Inc that investors may wish to consider to help them evaluate NOVN as an investment opportunity.

Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing

NEW YORK, June 29, 2020 -- Life Sciences Investor Forum today announced that the presentations from the June 25th conference are now available for on-demand viewing at.

Yahoo | June 29, 2020

How gene therapy and CRISPR are helping to cure blindness

In recent months, even as our attention has been focused on the coronavirus outbreak, there have been a slew of scientific breakthroughs in treating diseases that cause blindness. Researchers at U.S.-based Editas Medicine (EDIT)  and Ireland-based Allergan (now owned by AbbVie (ABBV) ) have administered CRISPR for the first time to a person with a genetic disease. This landmark treatment uses the CRISPR approach to a specific mutation in a gene linked to childhood blindness.

Yahoo | June 26, 2020

Novan to conduct additional SB206 trial for skin infection

Novan (NOVN) will conduct a new Phase 3 clinical trial, B-SIMPLE4, evaluating  SB206 for the treatment of molluscum.The Company anticipates that its current cash position will be sufficient to fund the trial. Patient enrollment is targeted in September 2020. Top-line efficacy results expected in late H2 2021.Shares are up 10% premarket....

Seeking Alpha | June 25, 2020

Novan Anticipates Current Cash Position Provides Sufficient Capital to Conduct Additional SB206 Phase 3 Pivotal Trial

Novan, Inc. ("the Company" or "Novan") (NOVN) today announced that the Company anticipates that its current cash position will be sufficient to fund costs associated with conducting an additional Phase 3 pivotal trial for SB206 as a treatment for molluscum, or B-SIMPLE4 (Berdazimer Sodium In Molluscum Patients with Lesions). Since June 1, 2020, the Company has secured approximately $16.9 million in capital from the use of common stock purchase agreements with Aspire Capital Fund, LLC and the exercise of common stock warrants sold in its March 2020 public offering. The Company is targeting enrolling the first patient for B-SIMPLE4 in September 2020 and, if the trial is initiated on this timetable and not further impacted by the COVID-19 pandemic, top-line efficacy results would be targ...

Yahoo | June 25, 2020

Novan to Present at Virtual Life Sciences Investor Forum on June 25

Novan, Inc. (“the Company” or “Novan”) (NOVN) today announced that Paula Brown Stafford, the Company’s President and Chief Executive Officer, will present a corporate overview at the Life Sciences Investor Forum on Thursday, June 25, 2020 at 2:00 p.m. Eastern. This will be a live, interactive online event where investors are invited to ask the company questions in real-time. The presentation and Q&A session will be webcast live and can be accessed through the Events page of the For Investors section of the Company's website at https://novan.gcs-web.com/events or at www.lifesciencesinvestorforum.com.

Yahoo | June 24, 2020

Read More 'NOVN' Stories Here

NOVN Price Returns

1-mo 23.19%
3-mo 18.49%
6-mo -21.54%
1-year -82.04%
3-year -87.39%
5-year N/A
YTD -83.86%
2019 280.72%
2018 -80.33%
2017 -84.38%
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.178 seconds.